LA JOLLA, Calif.--(BUSINESS WIRE)--Traversa Therapeutics, Inc., a privately held developer of RNAi delivery technologies, announced today the completion of a $2 million Series A financing led by the San Diego Tech Coast Angels and joined by investors Mesa Verde Venture Partners and Morningside Group.
